Literature DB >> 15322339

Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome.

Yuki Takigawa1, Motoko Nagano-Fujii, Lin Deng, Rachmat Hidajat, Motofumi Tanaka, Hiroyuki Mizuta, Hak Hotta.   

Abstract

RNA interference (RNAi) is a phenomenon in which small interfering RNA (siRNA), an RNA duplex 21 to 23 nucleotides (nt) long, or short hairpin RNA (shRNA) resembling siRNA, mediates degradation of the target RNA molecule in a sequence-specific manner. RNAi is now expected to be a useful therapeutic strategy for hepatitis C virus (HCV) infection. In the present study we compared the efficacy of a number of shRNAs directed against different target regions of the HCV genome, such as 5'-untranslated region (5'UTR) (nt 286 to 304), Core (nt 371 to 389), NS3-1 (nt 2052 to 2060), NS3-2 (nt 2104 to 2122), and NS5B (nt 7326 to 7344), all of which except for NS5B are conserved among most, if not all, HCV subtype 1b (HCV-1b) isolates in Japan. We utilized two methods to express shRNAs, one utilizing an expression plasmid (pAVU6+27) and the other utilizing a recombinant lentivirus harboring the pAVU6+27-derived expression cassette. Although 5'UTR has been considered to be the most suitable region for therapeutic siRNA and/or shRNA because of its extremely high degree of sequence conservation, we observed only a faint suppression of an HCV subgenomic replicon by shRNA against 5'UTR. In both plasmid-and lentivirus-mediated expression systems, shRNAs against NS3-1 and NS5B suppressed most efficiently the replication of the HCV replicon without suppressing host cellular gene expression. Synthetic siRNA against NS3-1 also inhibited replication of the HCV replicon in a dose-dependent manner. Taken together, the present results imply the possibility that the recombinant lentivirus expressing shRNA against NS3-1 would be a useful tool to inhibit HCV-1b infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322339     DOI: 10.1111/j.1348-0421.2004.tb03556.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  21 in total

Review 1.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 2.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

Review 3.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Authors:  Henry Fechner; Isaac Sipo; Dirk Westermann; Sandra Pinkert; Xiaomin Wang; Lennart Suckau; Jens Kurreck; Heinz Zeichhardt; Oliver Müller; Roland Vetter; Volker Erdmann; Carsten Tschope; Wolfgang Poller
Journal:  J Mol Med (Berl)       Date:  2008-06-12       Impact factor: 4.599

5.  Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA.

Authors:  Usman Ali Ashfaq; Muhammad Ansar; Muhammad Tahir Sarwar; Tariq Javed; Sidra Rehman; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-03-10       Impact factor: 4.099

6.  Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA.

Authors:  Muhammad Ansar; Usman Ali Ashfaq; Imran Shahid; Muhammad Tahir Sarwar; Tariq Javed; Sidra Rehman; Sajida Hassan; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-05-02       Impact factor: 4.099

Review 7.  siRNAs: potential therapeutic agents against hepatitis C virus.

Authors:  Usman A Ashfaq; Muhammad Z Yousaf; Maida Aslam; Rahat Ejaz; Shah Jahan; Obaid Ullah
Journal:  Virol J       Date:  2011-06-06       Impact factor: 4.099

8.  Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA.

Authors:  Brian J Geiss; Theodore C Pierson; Michael S Diamond
Journal:  Virol J       Date:  2005-06-28       Impact factor: 4.099

9.  Evaluation of canonical siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication--a comparative study.

Authors:  Bruno Carneiro; Ana Cláudia Silva Braga; Mariana Nogueira Batista; Mark Harris; Paula Rahal
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 10.  Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives.

Authors:  Josune Torrecilla; Alicia Rodríguez-Gascón; María Ángeles Solinís; Ana del Pozo-Rodríguez
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.